DCTH logo

DCTH
Delcath Systems Inc

26,277
Mkt Cap
$302.24M
Volume
1.14M
52W High
$18.23
52W Low
$8.39
PE Ratio
1,004.65
DCTH Fundamentals
Price
$8.64
Prev Close
$8.68
Open
$8.68
50D MA
$10.79
Beta
1.05
Avg. Volume
1.07M
EPS (Annual)
-$0.9254
P/B
2.66
Rev/Employee
$387,552.08
Loading...
Loading...
News
all
press releases
Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the...
Business Wire·12h ago
News Placeholder
More News
News Placeholder
Stephens Has Lowered Expectations for Delcath Systems (NASDAQ:DCTH) Stock Price
Stephens decreased their price target on Delcath Systems from $25.00 to $18.00 and set an "overweight" rating for the company in a research note on Wednesday...
MarketBeat·18h ago
News Placeholder
Delcath Systems, Inc. (DCTH) Q3 Earnings Match Estimates
Delcath Systems (DCTH) delivered earnings and revenue surprises of 0.00% and +0.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results...
Business Wire·3d ago
News Placeholder
Delcath Systems to Host Third Quarter 2025 Earnings Call
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on...
Business Wire·17d ago
News Placeholder
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for...
Business Wire·20d ago
News Placeholder
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2...
Business Wire·20d ago
News Placeholder
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates
Delcath Systems (DCTH) delivered earnings and revenue surprises of +250.00% and +9.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -3.33% and -55.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Is the Options Market Predicting a Spike in Delcath Systems Stock?
Investors need to pay close attention to DCTH stock based on the movements in the options market lately.
Zacks·4mo ago

Latest DCTH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.